PHASE I DOUBLE- BLIND, PLACEBO-CONTROLLED TRIAL OF 0.3MG LINACLOTIDE DELAYED-RELEASE (DR1) TO DEMONSTRATE COLORECTAL BIOACTIVITY IN HEALTHY VOLUNTEERS

Mayo Clinic Rochester, Rochester MN

Investigators

Abstract

Phase I Randomized Trial of 0.3 mg Linaclotide ?Phase I Double-Blind, Placebo-Controlled Trial of 0.3 mg Linaclotide Delayed-Release (DR1) to Demonstrate Colorectal Bioactivity in Healthy Volunteers